Literature DB >> 26187515

Influence of Posttransplant Lymphoproliferative Disorder on Survival in Children After Heart Transplantation.

Don Hayes1,2,3, Christopher K Breuer4,5, Edwin M Horwitz6,7, Andrew R Yates6,8,9, Joseph D Tobias10,9,11, Toshiharu Shinoka4,12.   

Abstract

The influence of posttransplant lymphoproliferative disorder (PTLD) on long-term survival in children after heart transplantation (HTx) is not well studied. The United Network for Organ Sharing database was queried from 1987 to 2013 for data on PTLD in relation to induction immunosuppression and recipient Epstein-Barr virus status in children (<18 years of age) who underwent HTx. Of 6818 first-time pediatric heart transplants, 5169 had follow-up data on posttransplant malignancy, with 360 being diagnosed with PTLD. Univariate Cox analysis identified diminished survival after PTLD onset using a time-varying measure of PTLD (HR 2.208; 95 % CI 1.812, 2.689; p < 0.001), although Kaplan-Meier survival functions found no difference in survival between the group ever diagnosed with PTLD and the non-PTLD reference group (log-rank test: χ 1 (2)  = 0.02; p = 0.928). A multivariate Cox model found a greater mortality hazard associated with the development of PTLD after adjusting for recipient EBV seronegativity and other covariates (HR 3.024; 95 % CI 1.902, 4.808; p < 0.001). Induction immunosuppression at time of HTx did not significantly influence posttransplant mortality. The development of PTLD adversely influenced long-term survival in children after HTx after adjusting for confounding variables.

Entities:  

Keywords:  Children; Heart transplantation; Pediatrics; Posttransplant lymphoproliferative disorder; Survival

Mesh:

Year:  2015        PMID: 26187515     DOI: 10.1007/s00246-015-1229-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  15 in total

1.  The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report--2014; focus theme: retransplantation.

Authors:  Anne I Dipchand; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Fabienne Dobbels; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Roger D Yusen; Josef Stehlik
Journal:  J Heart Lung Transplant       Date:  2014-08-14       Impact factor: 10.247

Review 2.  Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.

Authors:  Gyula Végso; Melinda Hajdu; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2010-12-31       Impact factor: 3.201

Review 3.  Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation.

Authors:  Hideaki Ohta; Norihide Fukushima; Keiichi Ozono
Journal:  Int J Hematol       Date:  2009-08-12       Impact factor: 2.490

4.  Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States.

Authors:  V R Dharnidharka; K E Lamb; J A Gregg; H-U Meier-Kriesche
Journal:  Am J Transplant       Date:  2012-01-06       Impact factor: 8.086

Review 5.  Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.

Authors:  J P Nourse; K Jones; M K Gandhi
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

6.  A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.

Authors:  R Chinnock; S A Webber; A I Dipchand; R N Brown; J F George
Journal:  Am J Transplant       Date:  2012-10-16       Impact factor: 8.086

7.  Malignancy after heart transplantation: incidence, prognosis and risk factors.

Authors:  M G Crespo-Leiro; L Alonso-Pulpón; J A Vázquez de Prada; L Almenar; J M Arizón; V Brossa; J F Delgado; J Fernandez-Yañez; N Manito; G Rábago; E Lage; E Roig; B Diaz-Molina; D Pascual; J Muñiz
Journal:  Am J Transplant       Date:  2008-05       Impact factor: 8.086

8.  Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients.

Authors:  T Haque; J A Thomas; K I Falk; R Parratt; B J Hunt; M Yacoub; D H Crawford
Journal:  J Gen Virol       Date:  1996-06       Impact factor: 3.891

9.  Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.

Authors:  S Schubert; H Abdul-Khaliq; H B Lehmkuhl; M Yegitbasi; P Reinke; C Kebelmann-Betzig; K Hauptmann; U Gross-Wieltsch; R Hetzer; F Berger
Journal:  Pediatr Transplant       Date:  2008-06-01

10.  Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.

Authors:  A Chadburn; N Suciu-Foca; E Cesarman; E Reed; R E Michler; D M Knowles
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

View more
  2 in total

1.  Long-Term Evaluation of Post-transplant Lymphoproliferative Disorders in Paediatric Heart Transplantation in Sao Paulo, Brazil.

Authors:  Adam Arshad; Estela Azeka; Samia Barbar; Raphael Marcondes; Adailson Siqueira; Luiz Benvenuti; Nana Miura; Marcelo Jatene; Vicente Odone Filho
Journal:  Pediatr Cardiol       Date:  2019-09-10       Impact factor: 1.655

Review 2.  A Review of Induction with Rabbit Antithymocyte Globulin in Pediatric Heart Transplant Recipients.

Authors:  Martin Schweiger; Andreas Zuckermann; Andres Beiras-Fernandez; Michael Berchtolld-Herz; Udo Boeken; Jens Garbade; Stephan Hirt; Manfred Richter; Arjang Ruhpawar; Jan Dieter Schmitto; Felix Schönrath; Rene Schramm; Uwe Schulz; Markus J Wilhelm; Markus J Barten
Journal:  Ann Transplant       Date:  2018-05-15       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.